Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.66 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.66 |
| ▸ | CCR3 | P51677 | 3/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.57 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912161 | 0.90 | PRMT6 (0.68) | PRMT6CARM1CCR3KCNH2 | |
| SCHEMBL7698046 | 0.89 | CCR3 (0.71) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL12041242 | 0.87 | KCNH2 (0.68) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL13554188 | 0.85 | PRMT6 (0.51) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL12041321 | 0.84 | KCNH2 (0.61) | PRMT6CARM1CCR3KCNH2PRMT3 | |
| SCHEMBL12041299 | 0.84 | KCNH2 (0.61) | PRMT6CARM1CCR3KCNH2SIGMAR1 | |
| SCHEMBL23719076 | 0.84 | CCR3 (0.80) | PRMT6CARM1CCR3PRMT3PRMT1 | |
| SCHEMBL8262506 | 0.84 | CCR3 (0.80) | PRMT6CARM1CCR3PRMT3PRMT1 | |
| SCHEMBL6218861 | 0.84 | CCR3 (0.80) | PRMT6CARM1CCR3PRMT3PRMT1 | |
| SCHEMBL19363866 | 0.84 | KCNH2 (0.74) | PRMT6CARM1CCR3KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | PRMT6 1733/4885CARM1 2432/4885CCR3 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.